Upgrade to SI Premium - Free Trial

Enanta Pharma (ENTA)

11.31 -0.36 (3.08%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/16/26)

Latest Headlines

Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026 October 13, 2026 7:00 AM - BizWire H.C. Wainwright Reiterates Buy Rating on Enanta Pharmaceuticals (ENTA) September 25, 2026 6:49 AM - StreetInsider H.C. Wainwright Reiterates Buy Rating on Enanta Pharmaceuticals (ENTA) September 23, 2026 6:53 AM - StreetInsider Enanta Pharmaceuticals to Participate in September Investor Conferences September 1, 2026 7:00 AM - BizWire Form SCHEDULE 13G/A ENANTA PHARMACEUTICALS Filed by: Deep Track Capital, LP August 14, 2026 8:26 AM - SEC Filing Form SCHEDULE 13G/A ENANTA PHARMACEUTICALS Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C. August 14, 2026 8:19 AM - SEC Filing Form 10-Q ENANTA PHARMACEUTICALS For: Jun 30 August 12, 2026 7:01 AM - SEC Filing Form 8-K ENANTA PHARMACEUTICALS For: Aug 10 August 10, 2026 4:06 PM - SEC Filing Enanta Pharma (ENTA) Misses Q3 EPS by 17c August 10, 2026 4:02 PM - StreetInsider Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026 August 10, 2026 4:01 PM - BizWire Form 4 ENANTA PHARMACEUTICALS For: Aug 08 Filed by: Rottinghaus Scott T. August 10, 2026 9:01 AM - SEC Filing Full Article List